Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder

Therapeutic Advances in Urology

Volumn 6, Issue 5, 2014, Pages 181-191

  Cookson, Michael S ^a   Chang, Sam S ^a   Lihou, Christine ^b   li, Thomas ^b   Harper, Samira Q ^b   Lang, Zhihui ^b   Tutrone, Ronald F ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

^c Chesapeake Urology Research Associates   (United States)

Author keywords

bladder cancer; chemotherapy; cystectomy; disease progression; recurrence

Indexed keywords

VALRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER SPASM; CANCER SURVIVAL; CARCINOMA IN SITU; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; EVENT FREE SURVIVAL; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON MUSCLE INVASIVE BLADDER CANCER; POLLAKISURIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; URINARY URGENCY;

EID: 84906685940     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287214541798     Document Type: Article

References (20)

1. Blum R. Garnick M. Israel M. Panellos G. Henderson I. Frei E. III (1981) Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res 76: 7–15.
2. Bohle A. Jocham D. Bock P. (2003) Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169: 90–95.
3. Bostrom P. Kossi J. Laato M. Nurmi M. (2009) Risk factors for mortality and morbidity related to radical cystectomy. BJU Int 103: 191–196.
4. Brausi M. Witjes J. Lamm D. Persad R. Palou J. Colombel M. (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. J Urol 186: 2158–2167.
5. Clark P. Stein J. Groshen S. Cai J. Miranda G. Lieskovsky G. (2005) Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer 104: 36–43.
6. Dinney C. Greenberg R. Steinberg G. (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol 31: 1635–1642.
7. Endo Pharmaceuticals (2011) Valstar® (valrubicin). Full prescribing information. Chadds Ford, PA: Endo Pharmaceuticals Inc.
8. Gilbert S. Wood D. Dunn R. Weizer A. Lee C. Montie J. (2007) Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 109: 1756–1762.
9. Greenberg R. Bahnson R. Wood D. Childs S. Bellingham C. Edson M. (1997) Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49: 471–475.
10. Hall M. Chang S. Dalbagni G. Pruthi R. Seigne J. Skinner E. (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178: 2314–2330.
11. Hess D. (2004) Retrospective studies and chart reviews. Respir Care 49: 1171–1174.
12. Ignatoff J. Chen Y. Greenberg R. Pow-Sang J. Messing E. Wilding G. (2009) Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guérin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol 27: 496–501.
13. Liberman D. Lughezzani G. Sun M. Alasker A. Thuret R. Abdollah F. (2011) Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology 77: 660–666.
14. Montie J. Clark P. Agerwal N. Eisenberger M. El-Galley R. Greenberg R. (2011) NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM): Bladder Cancer, version 2.2011. Fort Washington, PA: National Comprehensive Cancer Network.
15. Organon Teknika (2009) TICE® BCG (BCG live [for intravesical use]). Full prescribing information. Durham, NC: Organon Teknika Corporation LLC.0
16. Pansadoro V. Emiliozzi P. De Paula F. Scarpone P. Pansadoro A. Sternberg C. (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. Urology 59: 227–231.
17. Patterson A. Greenberg R. Weems L. Bahnson R. Wajsman Z. Israel M. (2000) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 56: 232–235.
18. Steinberg G. Bahnson R. Brosman S. Middleton R. Wajsman Z. Wehle M. (2000) Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163: 761–767.
19. Steinberg G. Smith N. Ryder K. Strangman N. Slater S. (2011) Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. Postgrad Med 123: 28–34.
20. Svatek R. Fisher M. Matin S. Kamat A. Grossman H. Nogueras-Gonzalez G. (2010) Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol 183: 929–934.